Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.500 +0.130 (+9.49%)
Streaming Delayed Price Updated: 12:33 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 672,799
Open 1.440
Bid (Size) 1.490 (26)
Ask (Size) 1.500 (26)
Prev. Close 1.370
Today's Range 1.420 - 1.680
52wk Range 0.6302 - 1.910
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga

Performance

YTD
+120.3%
+120.3%
1 Month
+29.3%
+29.3%
3 Month
+66.7%
+66.7%
6 Month
+54.6%
+54.6%
1 Year
+85.2%
+85.2%

More News

Read More
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
Via Stocktwits
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study
Via Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
What is the current price of Tiziana Life Sciences Ltd - Common Shares?
The current price of Tiziana Life Sciences Ltd - Common Shares is 1.500
When was Tiziana Life Sciences Ltd - Common Shares last traded?
The last trade of Tiziana Life Sciences Ltd - Common Shares was at 05/23/25 12:33 PM ET
What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 291.92M
How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
Tiziana Life Sciences Ltd - Common Shares has 292M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.